title: Nine-month angiographic and intravascular ultrasound outcomes after resolute zotarolimus-eluting stent implantation for the treatment of in-stent restenosis.
abstract: OBJECTIVE
  We aimed to evaluate the mid-term outcomes of resolute zotarolimus-eluting stent (R-ZES) implantation for in-stent restenosis (ISR).
  
  
  BACKGROUND
  There has been a paucity of data regarding the effects of new-generation drug-eluting stent to treat ISR.
  
  
  METHODS
  From 2009 to 2010, a total of 98 patients with 98 ISR lesions were prospectively enrolled after R-ZES implantation for the treatment of ISR. Among 98 patients, 73 patients underwent follow-up angiography at 9 months. Serial intravascular ultrasound (IVUS) at both postprocedure and 9 months was evaluated in 55 patients. The overlapped segment of R-ZES was defined as the portion of R-ZES superimposed on previous stent.
  
  
  RESULTS
  Late loss and binary restenosis rate were 0.3 ± 0.5 mm and 5.5% at 9 months. On IVUS, the percentage of neointimal volume and maximum percentage of neointimal area were 3.9 ± 6.3% and 17.3 ± 15.5%, respectively. There was no significant change of vessel volume index between postprocedure and 9 months (16.9 ± 4.7 mm³ /mm vs. 17.1 ± 4.6 mm³ /mm, P = 0.251). Late-acquired incomplete stent apposition was observed in 5 (5/55, 9.1%) cases. Compared with nonoverlapped segments of R-ZES, the overlapped did not show larger neointimal volume index (0.3 ± 0.5 mm³ /mm vs. 0.2 ± 0.3 mm³ /mm, P = 0.187) on 9-month IVUS. During follow-up (median, 353 days), repeat target-lesion revascularization was performed in four cases, but there were no death or stent thrombosis.
  
  
  CONCLUSIONS
  This study suggested that R-ZES implantation for the treatment of ISR was effective up to 9 months and showed favorable vascular responses on serial IVUS assessment.
authors.affiliation: Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea.
authors.forename: Seung-Yul
authors.initials: SY
authors.lastname: Lee
authors.forename: Byeong-Keuk
authors.initials: BK
authors.lastname: Kim
authors.forename: Jung-Sun
authors.initials: JS
authors.lastname: Kim
authors.forename: Myeong-Ki
authors.initials: MK
authors.lastname: Hong
authors.forename: Deok-Kyu
authors.initials: DK
authors.lastname: Cho
authors.forename: Junghan
authors.initials: J
authors.lastname: Yoon
authors.forename: Dong Woon
authors.initials: DW
authors.lastname: Jeon
authors.forename: Nam-Ho
authors.initials: NH
authors.lastname: Lee
authors.forename: Hyuck Moon
authors.initials: HM
authors.lastname: Kwon
authors.forename: Yangsoo
authors.initials: Y
authors.lastname: Jang
mesh_terms: D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000175:diagnosis* / Q000628:therapy*; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013997:Time Factors; D016896:Treatment Outcome; D018084:Ultrasonography, Interventional
chemical_list: C489443:zotarolimus; D020123:Sirolimus